Is human papillomavirus vaccination useful for middle-aged women?
The paper analyzes the data available in the current scientific literature on the problem of human papillomavirus (HPV) vaccination in women over 25 years of age. Based on the data on the incidence and prevalence of HPV, sexual behavior and HPV transmission, and the lack of reliable immunity after natural infection, it is shown that sexually active middle-aged women are still at risk for a new HPV infection, which can lead to cervical cancer. HPV vaccines are immunogenic and safe in this age group and should be proposed to adult women. A combination of screening technologies and HPV vaccination has a great potential for reducing the incidence of cervical cancer in women of all ages.Minkina G.N.
Keywords
human papillomavirus
infection
vaccination
cervical cancer
age
References
1. Forman D., de Martel C., Lacey C.J., Soerjomataram I., Lortet-Tieulent J., Bruni L. et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012; 30(Suppl. 5): F12-23.
2. American Cancer Society. Cancer facts and figs. 2015 [online]. Available at:http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf
3. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России; 2017. 249с. [Kaprin A.D., Starinsky V.V., Petrova G.V., ed. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Moscow: MNIOI im. P.A. Herzen - branch of the NWIRTC of the Ministry of Health of Russia; 2017. 249p. (in Russian)]
4. Drolet M., Bénard É., Boily M.C., Ali H., Baandrup L., Bauer H. et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 2015; 15(5): 565-80.
5. Garland S.M., Kjaer S.K., Muñoz N., Block S.L., Brown D.R., DiNubile M.J. et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin. Infect. Dis. 2016; 63(4): 519-27.
6. Castle P.E., Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol. Infect. 2016; 144(3): 449-68.
7. Maver P.J., Poljak M. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: a literature review. 2018; 36(36): 5416-23.
8. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol. Rec. 2017; 92(19): 241-68. Available at: http://www.who.int/wer
9. European Centre for Disease Prevention and Control. Introduction of HPV vaccines in EU countries – an update. Stockholm: ECDC; 2012. Available at: www.ecdc.europa.eu
10. Bailey H.H., Chuang L.T., duPont N.C., Eng C., Foxhall L.E., Merrill J.K. et al. American Society of Clinical Oncology Statement: Human papillomavirus vaccination for cancer prevention. J. Clin. Oncol. 2016; 34(15): 1803-12.
11. Markowitz L.E., Dunne E.F., Saraiya M., Chesson H.W., Curtis C.R., Gee J. et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2014; 63(RR-05): 1-30.
12. Elfström K.M., Dillner J., Arnheim-Dahlström L. Organization and quality of HPV vaccination programs in Europe. Vaccine. 2015; 33(14): 1673-81.
13. Краснопольский В.И., Логутова Л.С., Зароченцева Н.В., Белая Ю.М., Тамазян Г.В., Гридчик А.Л., Булычева Е.С. Результаты вакцинопрофилактики ВПЧ-ассоциированных заболеваний и рака шейки матки в Московской области. Российский вестник акушера-гинеколога. 2015; 15(3): 9-14. [Krasnopolsky V.I., Logutova L.S., Zarochentseva N.V., Belaya Yu.M., Tamazyan G.V., Gridchik A.L., Bulycheva Е.S. Results of vaccine prophylaxis for HPV-associated diseases and cervical cancer in the Moscow Region.. Rossiyskiy vestnik akushera-ginekologa. 2015; 15(3): 9-14. (in Russian)]
14. Couto E., Sæterdal I., Juvet L.K., Klemp M. HPV catch-up vaccination of young women: a systematic review and meta-analysis. BMC Public Health. 2014; 14: 867.
15. WHO. Immunization,vaccines and biologicals database, as of 31 March 2017. Available at: http://www.who.int/entity/immunization/monitoring_surveillance/VaccineIntroStatus.pptx Accessed February 2017
16. Grant L.A., Dunne E.F., Chesson H., Markowitz LE. Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States. Vaccine. 2011; 29(13): 2365-70.
17. Plotnick M., Craig C. Should HPV vaccination be offered to mid-adult women? J. Obstet. Gynaecol. Can. 2017; 39(5): 361-5.
18. Maglennon G.A., McIntosh P., Doorbar J. Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology. 2011; 414(2): 153-63.
19. Gravitt P.E. Evidence and impact of human papillomavirus latency. Open Virol. J. 2012; 6: 198-203.
20. Moscicki A.B., Schiffman M., Burchell A., Albero G., Giuliano A.R., Goodman M.T. et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 2012; 30(Suppl. 5): F24-33.
21. Mollers M., Vossen J.M., Scherpenisse M., van der Klis F.R., Meijer C.J., de Melker H.E. Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme. J. Med. Virol. 2013; 85(8): 1379-85.
22. Stanley M.A., Sterling J.C. Host responses to infection with human papillomavirus. Curr. Probl. Dermatol. 2014; 45: 58-74.
23. Wentzensen N., Rodriguez A.C., Viscidi R., Herrero R., Hildesheim A., Ghosh A. et al. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J. Infect. Dis. 2011; 204(1): 94-102.
24. Schiller J.T., Castellsagué X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012; 30(Suppl. 5): F123-38.
25. Rositch A.F., Burke A.E., Viscidi R.P., Silver M.I., Chang K., Gravitt P.E. Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res. 2012; 72(23): 6183-90.
26. Winer R.L., Hughes J.P., Feng Q., Stern J.E., Xi L.F., Koutsky L.A. Incident detection of high-risk human papillomavirus infections in a cohort of high-risk women aged 25-65 years. J. Infect. Dis. 2016; 214(5): 665-75.
27. Fu T.C., Carter J.J., Hughes J.P., Feng Q., Hawes S.E., Schwartz S.M. et al. Re-detection vs. new acquisition of high-risk human papillomavirus in mid-adult women. Int. J. Cancer. 2016; 139(10): 2201-12.
28. Maucort-Boulch D., Plummer M., Castle P.E., Demuth F., Safaeian M., Wheeler C.M., Schiffman M. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int. J. Cancer. 2010; 126(3): 684-91.
29. Rodríguez A.C., Schiffman M., Herrero R., Hildesheim A., Bratti C., Sherman M.E. et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J. Natl. Cancer Inst. 2010; 102(5): 315-24.
30. Skinner S.R., Wheeler C.M., Romanowski B., Castellsagué X., Lazcano-Ponce E., Del Rosario-Raymundo M.R. et al. Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. Int. J. Cancer. 2016;138(10): 2428-38.
31. Arbyn M., Xu L., Simoens C., Martin-Hirsch P.P. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst. Rev. 2018; (5): CD009069.
Received 08.06.2018
Accepted 22.06.2018
About the Authors
Minkina, Galina N., Professor of A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia.127473, Russia, Moscow, Delegatskaya str. 20/1. Tel.: +79037928215. E-mail: minkinagn@mail.ru
For citations: Minkina G.N. Is human papillomavirus vaccination useful for middle-aged women? Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (9): 152-6. (in Russian)
https://dx.doi.org/10.18565/aig.2018.9.152-156
Similar Articles
